From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels <70 mg/dL with PCSK9 inhibitors? And in which patient subgroups do these agents offer unique outcome-related benefits?

From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels <70 mg/dL with PCSK9 inhibitors? And in which patient subgroups do these agents offer unique outcome-related benefits?

CLICK HERE FOR CME CREDIT

From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Professor of Medicine Division of Endocrinology, Metabolism & Lipid Research Washington University in St. Louis St. Louis, MO